Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 258

Results For "CRO"

4631 News Found

Laurus Labs to increase stake in ImmunoACT to 33.86%
News | June 01, 2023

Laurus Labs to increase stake in ImmunoACT to 33.86%

This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19


HMD supplied 1.75 billion syringes of the total 13.3 billion COVID 19 vaccines administered globally
News | June 01, 2023

HMD supplied 1.75 billion syringes of the total 13.3 billion COVID 19 vaccines administered globally

HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date


PharmaLytica returns to Hyderabad
News | May 31, 2023

PharmaLytica returns to Hyderabad

With over 150 leading companies, 300+ topline brands and knowledge-led conference sessions, the event is set to make a grand return to the South


Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr
News | May 30, 2023

Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr

The company reported lifetime high EBIDTA of Rs. 250 crores


Hikal posts FY23 PAT at Rs. 36 Cr
News | May 30, 2023

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22


Jubilant Pharmova posts Q4FY23 consolidated loss at Rs. 97.84 Cr
News | May 30, 2023

Jubilant Pharmova posts Q4FY23 consolidated loss at Rs. 97.84 Cr

The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023


NATCO records FY23 PAT at Rs. 715.3 Cr
News | May 30, 2023

NATCO records FY23 PAT at Rs. 715.3 Cr

The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.


Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr
News | May 29, 2023

Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr

US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore


Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22
News | May 29, 2023

Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22

Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239